

<b>REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE COMMUNITY</b>
--

*To be filled in by the applicant*

The questions in this form for the request for authorisation from the Competent Authority are also relevant for the opinion from an Ethics Committee (it represents module 1 of the form for applying to an ethics committee) and can be used as part of that application. Please indicate the relevant purpose in a box below.

**REQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY:** Yes ●  
**REQUEST FOR OPINION OF THE ETHICS COMMITTEE:** No ●

### A. TRIAL IDENTIFICATION

A.1	Member State in which the submission is being made:	<b>Denmark - DHMA</b>
A.2	EudraCT number:	<b>2017-003829-15</b>
A.3	Full title of the trial: <b>English</b>	<b>Agents Intervening against Delirium in the Intensive Care Unit (AID-ICU)</b>
A.3.1	Title of the trial for lay people, in easily understood, i.e. non-technical, language: <b>English</b>	<b>Pharmacological treatment of organic psychosis in critically ill adults</b>
A.3.2	Name or abbreviated title of the trial where available: <b>English</b>	<b>AID-ICU</b>
A.4	Sponsor's protocol code number, version and date <sup>1</sup> :	
A.4.1	Sponsor's protocol code number:	<b>AID-ICU</b>
A.4.2	Sponsor's protocol version:	<b>4.2</b>
A.4.3	Sponsor's protocol date:	<b>2019-06-06</b>
A.5	Additional international study identifiers (e.g. WHO, ISRCTN <sup>2</sup> , US NCT Number <sup>3</sup> ) if available	
A.5.1	ISRCTN number:	
A.5.2	US NCT number:	
A.5.3	WHO Universal Trial Number (UTN):	
A.5.4	Other Identifier: <b>ClinicalTrials.gov</b>	<b>NCT03392376</b>
A.6	Is this a resubmission? If 'Yes', indicate the resubmission letter <sup>4</sup> :	<b>No ●</b> <b>First Submission</b>
A.7	Is the trial part of an agreed Paediatric Investigation Plan?	<b>No ●</b>
A.8	EMA Decision number of Paediatric Investigation Plan:	

## B. IDENTIFICATION OF THE SPONSOR RESPONSIBLE FOR THE REQUEST

<b>B.1</b>	<b>SPONSOR</b>
B.1.1	Name of organisation: <b>Zealand University Hospital</b>
B.1.2	Name of the person to contact:
B.1.2.1	Given name <b>Lone</b>
B.1.2.2	Middle name
B.1.2.3	Family name <b>Musaeus Poulsen</b>
B.1.3	Address:
B.1.3.1	Street address <b>Lykkebaekvej 1</b>
B.1.3.2	Town/city <b>Koege</b>
B.1.3.3	Post code <b>4600</b>
B.1.3.4	Country <b>Denmark</b>
B.1.4	Telephone number: <b>+45 47326451</b>
B.1.5	Fax number:
B.1.6	E-mail: <b>Imp@regionsjaelland.dk</b>
<b>B.2</b>	<b>LEGAL REPRESENTATIVE<sup>5</sup> OF THE SPONSOR IN THE COMMUNITY FOR THE PURPOSE OF THIS TRIAL</b> (if different from the sponsor)
B.2.1	Name of organisation:
B.2.2	Name of person to contact:
B.2.2.1	Given name
B.2.2.2	Middle name
B.2.2.3	Family name
B.2.3	Address:
B.2.3.1	Street address
B.2.3.2	Town/city
B.2.3.3	Post code
B.2.3.4	Country
B.2.4	Telephone number:
B.2.5	Fax number:
B.2.6	E-mail:
<b>B.3</b>	<b>STATUS OF THE SPONSOR:</b>
B.3.1	Commercial: <b>No •</b>
B.3.2	Non commercial: <b>Yes •</b>
<b>B.4</b>	<b>Source(s) of Monetary or Material Support for the clinical trial (repeat as necessary):</b>
B.4.1	Name of organisation: <b>Innovations Fund Denmark</b>
B.4.2	Country: <b>Denmark</b>
<b>B.4</b>	<b>Source(s) of Monetary or Material Support for the clinical trial (repeat as necessary):</b>
B.4.1	Name of organisation: <b>Zealand University Hospital</b>
B.4.2	Country: <b>Denmark</b>
<b>B.4</b>	<b>Source(s) of Monetary or Material Support for the clinical trial (repeat as necessary):</b>
B.4.1	Name of organisation: <b>The Regions medicine foundation</b>
B.4.2	Country: <b>Denmark</b>
<b>B.5</b>	<b>Contact point<sup>6</sup> designated by the sponsor for further information on the trial</b>
B.5.1	Name of organisation: <b>Department of Anaesthesia and intensive Care Medicine, Zealand University Hospital, Koege</b>
B.5.2	Functional name of contact point (e.g. "Clinical Trial Information Desk"): <b>Lone Musaeus Poulsen</b>

B.5.3	Address:	
B.5.3.1	Street address	<b>Lykkebaekvej 1</b>
B.5.3.2	Town/city	<b>Koege</b>
B.5.3.3	Post code	<b>4600</b>
B.5.3.4	Country	<b>Denmark</b>
B.5.4	Telephone number:	<b>+45 47326451</b>
B.5.5	Fax number:	
B.5.6	E-mail: (use a functional e-mail address rather than a personal one)	<b>Imp@regionsjaelland.dk</b>

**C. APPLICANT IDENTIFICATION, (please tick the appropriate box)**

<b>C.1 REQUEST FOR THE COMPETENT AUTHORITY</b>	
C.1.1	Sponsor
C.1.2	Legal representative of the sponsor
C.1.3	Person or organisation authorised by the sponsor to make the application <b>Yes •</b>
C.1.4	Complete the details of the applicant below even if they are provided elsewhere on the form:
C.1.4.1	Name of Organisation: <b>Zealand University Hospital</b>
C.1.4.2	Name of contact person:
C.1.4.2.1	Given name <b>Nina Christine</b>
C.1.4.2.2	Middle name
C.1.4.2.3	Family name <b>Andersen-Ranberg</b>
C.1.4.3	Address:
C.1.4.3.1	Street address <b>Lykkebaekvej 1</b>
C.1.4.3.2	Town/city <b>Koege</b>
C.1.4.3.3	Post code <b>4600</b>
C.1.4.3.4	Country <b>Denmark</b>
C.1.4.4	Telephone number: <b>+45 47326493</b>
C.1.4.5	Fax number:
C.1.4.6	E-mail: <b>ncan@regionsjaelland.dk</b>
C.1.5	Request to receive a copy of CTA data as XML:
C.1.5.1	Do you want a copy of the CTA form data saved on EudraCT as an XML file? <b>Yes •</b>
C.1.5.1.1	If Yes provide the e-mail address(es) to which it should be sent (up to 5 addresses): <b>ncan@regionsjaelland.dk</b>
C.1.5.1.2	Do you want to receive this via password protected link(s)?? <b>No •</b>
If you answer No to question C.1.5.1.2 the .xml file will be transmitted by less secure e-mail link(s)	

## D. INFORMATION ON EACH IMP

Information on each 'bulk product' before trial-specific operations (blinding, trial specific packaging and labelling) should be provided in this section for each investigational medicinal product (IMP) being tested including each comparator and each placebo, if applicable. **For placebo go directly to D.8.** If the trial is performed with several products use extra pages and give each product a sequential number in D.1.1. If the product is a combination product, information should be given for each active substance.

<b>D.1 IMP IDENTIFICATION</b>		
Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial (assign numbers from 1-n):		
D.1.1	This refers to the IMP number:	<b>PR1</b>
D.1.2	IMP being tested	<b>Yes •</b>
D.1.3	IMP used as a comparator	<b>No •</b>
<b>D.2 STATUS OF THE IMP</b>		
D.2.1	Has the IMP to be used in the trial a marketing authorisation? <b>Yes •</b> <b>If the IMP has a marketing authorisation in the Member State concerned by this application, but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.</b>	
D.2.1.1	If 'Yes', specify the product to be used in the clinical trial:	
D.2.1.1.1	Trade name <b>Serenase/haldol</b>	
D.2.1.1.1.1	EV Product Code (where applicable)	
D.2.1.1.2	Name of the Marketing Authorisation Holder:	<b>Janssen-Cilag A/S</b>
D.2.1.1.3	Marketing Authorisation number (if Marketing Authorisation granted by a Member State):	<b>09661</b>
D.2.1.1.4	Is the IMP modified in relation to its Marketing Authorisation? <b>Yes •</b>	
D.2.1.1.4.1	If 'Yes', please specify: <b>The product will be blinded and relabeling of primary and secondary labels are thereby necessary. Secondary packaging will also be changed. There will be no changes to the IMP or primary packaging (ampule)</b>	
D.2.1.2	The country that granted the Marketing Authorisation	<b>Denmark</b>
D.2.1.2.1	Is this the Member State concerned with this application?	<b>Yes •</b>
D.2.2	Situations where an IMP to be used in the CT has a Marketing Authorisation in the Member State concerned, but the protocol allows that any brand of the IMP with a Marketing Authorisation in that Member State be administered to the trial subjects and it is not possible to clearly identify the IMP(s) in advance of the trial start	
D.2.2.1	In the protocol, is treatment defined only by active substance? <b>No •</b>	
D.2.2.1.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.2	In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS? <b>No •</b>	
D.2.2.2.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.3	The products to be administered as IMPs are defined as belonging to an ATC group <sup>9</sup> <b>Yes •</b>	
D.2.2.3.1	If 'Yes', give the ATC group of the applicable authorised codes in the ATC code field (level 3 or the level that can be defined) in D.3.3	
D.2.2.4	Other: <b>No •</b>	
D.2.2.4.1	If 'Yes', please specify:	
D.2.3	IMPD submitted:	
D.2.3.1	Full IMPD:	<b>No •</b>
D.2.3.2	Simplified IMPD:	<b>No •</b>

D.2.3.3	Summary of product characteristics (SmPC) only:	<b>Yes •</b>
D.2.4	Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community?	<b>No •</b>
D.2.4.1	If 'Yes' specify which Member States:	
D.2.5	Has the IMP been designated in this indication as an orphan drug in the Community?	<b>No •</b>
D.2.5.1	If 'Yes', give the orphan drug designation number <sup>10</sup> :	

D.2.6	Has the IMP been the subject of scientific advice related to this clinical trial?	<b>No •</b>
D.2.6.1	If 'Yes' to D.2.6, please indicate source of advice and provide a copy in the CTA request:	
D.2.6.1.1	CHMP <sup>11</sup> ?	<b>No •</b>
D.2.6.1.2	National Competent Authority?	<b>No •</b>

<b>D.3</b>	<b>DESCRIPTION OF THE IMP</b>	
D.3.1	Product name where applicable <sup>12</sup> :	
D.3.2	Product code where applicable <sup>13</sup> :	
D.3.3	ATC codes, if officially registered <sup>14</sup> :	<b>N05AD01</b>
D.3.4	Pharmaceutical form (use standard terms):	<b>Injection</b>
D.3.4.1	Is this a specific paediatric formulation?	<b>No •</b>
D.3.5	Maximum duration of treatment of a subject according to the protocol:	
	<b>Maximum 90 days</b>	
D.3.6	Dose allowed:	
D.3.6.1	For first trial only:	
	Specify per day or total	<b>Not Answered •</b>
	Specify total dose (number and unit):	
	Route of administration (relevant to the first dose):	
D.3.6.2	For all trials:	
	Specify per day or total	<b>Per day •</b>
	Specify total dose (number and unit):	<b>20 mg milligram(s)</b>
	Route of administration (relevant to the maximum dose):	<b>Intravenous use</b>
D.3.7	Routes of administration (use standard terms):	<b>Intravenous use</b>

D.3.8	Name of each active substance (INN or proposed INN if available):	
D.3.9	Other available name for each active substance ( provide all available):	
D.3.9.1	CAS <sup>15</sup> number	
D.3.9.2	Current sponsor code	
D.3.9.3	Other descriptive name	
D.3.9.4	EV Substance code	
D.3.9.5	Full Molecular formula	
D.3.9.6	Chemical/biological description of the Active Substance	
D.3.10	Strength (specify all strengths to be used):	
D.3.10.1	Concentration unit:	
D.3.10.2	Concentration type ("exact number", "range", "more than" or "up to"):	
D.3.10.3	Concentration (number).	

D.3.11	Type of IMP	
	Does the IMP contain an active substance:	
D.3.11.1	Of chemical origin?	<b>Yes •</b>
D.3.11.2	Of biological / biotechnological origin (other than Advanced Therapy IMP (ATIMP)?	<b>No •</b>
	Is this a:	
D.3.11.3	Advanced Therapy IMP (ATIMP)?	<b>No •</b>

D.3.11.3.1	Somatic cell therapy medicinal product <sup>16</sup> ?	No ●
D.3.11.3.2	Gene therapy medicinal product <sup>17</sup> ?	No ●
D.3.11.3.3	Tissue Engineered Product <sup>18</sup> ?	No ●
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device <sup>19</sup> )?	No ●
D.3.11.3.5	Has the Committee on Advanced Therapies issued a classification for this product?	No ●
D.3.11.3.5.1	If 'Yes' please provide that classification and its reference number:	
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy?	No ●
D.3.11.5	Radiopharmaceutical medicinal product?	No ●
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)?	No ●
D.3.11.7	Plasma derived medicinal product?	No ●
D.3.11.8	Extractive medicinal product?	No ●
D.3.11.9	Recombinant medicinal product?	No ●
D.3.11.10	Medicinal product containing genetically modified organisms?	No ●
D.3.11.10.1	Has the authorisation for contained use or release been granted?	No ●
D.3.11.10.2	Is it pending?	No ●
D.3.11.11	Herbal medicinal product?	No ●
D.3.11.12	Homeopathic medicinal product?	No ●
D.3.11.13	Another type of medicinal product?	No ●
D.3.11.13.1	If 'another type of medicinal product' specify the type of medicinal product:	
D.3.12	Mode of action ( <i>free text</i> <sup>20</sup> )	
D.3.13	Is it an IMP to be used in a first-in-human clinical trial?	No ●
D.3.13.1	If 'Yes', are there risk factors identified, according to the guidance FIH? <sup>21</sup>	

<b>D.4</b>	<b>SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC MODIFICATION)</b>	
D.4.1	Origin of cells	
D.4.1.1	Autologous	No ●
D.4.1.2	Allogeneic	No ●
D.4.1.3	Xenogeneic	No ●
D.4.1.3.1	If 'Yes', specify the species of origin:	
D.4.2	Type of cells	
D.4.2.1	Stem cells	No ●
D.4.2.2	Differentiated cells	No ●
D.4.2.2.1	If 'Yes', specify the type (e.g. keratinocytes, fibroblasts, chondrocytes...):	
D.4.2.3	Others:	No ●
D.4.2.3.1	If others, specify:	

<b>D.5</b>	<b>GENE THERAPY INVESTIGATIONAL MEDICINAL PRODUCTS</b>	
D.5.1	Gene(s) of interest:	
D.5.2	In vivo gene therapy:	No ●
D.5.3	Ex vivo gene therapy:	No ●
D.5.4	Type of gene transfer product	
D.5.4.1	Nucleic acid (e.g. plasmid):	No ●
	If 'Yes', specify if:	
D.5.4.1.1	Naked:	No ●
D.5.4.1.2	Complexed	No ●
D.5.4.2	Viral vector:	No ●
D.5.4.2.1	If 'Yes', specify the type: adenovirus, retrovirus, AAV, ...:	

D.5.4.3	Others	<b>No •</b>
D.5.4.3.1	If others, specify:	
D.5.5	Genetically modified somatic cells: If 'Yes', specify the origin of the cells:	<b>No •</b>
D.5.5.1	Autologous:	<b>No •</b>
D.5.5.2	Allogeneic:	<b>No •</b>
D.5.5.3	Xenogeneic:	<b>No •</b>
D.5.5.3.1	If 'Yes', specify the species of origin:	
D.5.5.4	Specify type of cells (hematopoietic stem cells...):	

<b>D.6 TISSUE ENGINEERED PRODUCT</b>		
The indication which determines that this is a Tissue Engineered Product as opposed to a Cell Therapy product is given in section E.1.1.		
D.6.1	Origin of cells	
D.6.1.1	Autologous	<b>No •</b>
D.6.1.2	Allogeneic	<b>No •</b>
D.6.1.3	Xenogeneic	<b>No •</b>
D.6.1.3.1	If 'Yes', specify the species of origin:	
D.6.2	Type of cells	
D.6.2.1	Stem cells	<b>No •</b>
D.6.2.2	Differentiated cells	<b>No •</b>
D.6.2.2.1	If 'Yes', specify the type of cells(e.g. keratinocytes, fibroblasts, chondrocytes, ...):	
D.6.2.3	Others:	<b>No •</b>
D.6.2.3.1	If others, specify:	

<b>D.7 PRODUCTS CONTAINING DEVICES (i.e. MEDICAL DEVICES, SCAFFOLDS ETC.)</b>		
D.7.1	Give a brief description of the device:	
D.7.2	What is the name of the device?	
D.7.3	Is the device implantable?	<b>No •</b>
D.7.4	Does this product contain:	
D.7.4.1	A medical device?	<b>No •</b>
D.7.4.1.1	Does this medical device have a CE mark?	<b>No •</b>
D.7.4.1.1.1	The notified body is:	
D.7.4.2	Bio-materials?	<b>No •</b>
D.7.4.3	Scaffolds?	<b>No •</b>
D.7.4.4	Matrices?	<b>No •</b>
D.7.4.5	Other?	<b>No •</b>
D.7.4.5.1	If other, specify:	

## D.8 INFORMATION ON PLACEBO (if relevant; repeat as necessary)

D.8.1	Is there a placebo:	<b>Yes •</b>
D.8.2	This refers to placebo number:	<b>PL1</b>
D.8.3	Pharmaceutical form:	<b>Injection</b>
D.8.4	Route of administration:	<b>Intravenous use</b>
D.8.5	Which IMP is it a placebo for? Specify IMP Number(s) from D.1.1	<b>PR1</b>



D.8.5.1	Composition, apart from the active substance(s):	
D.8.5.2	Is it otherwise identical to the IMP?	<b>Yes •</b>
D.8.5.2.1	If not, specify major ingredients:	

## D.9 SITE(S) WHERE THE QUALIFIED PERSON CERTIFIES BATCH RELEASE<sup>22</sup>

This section is dedicated to **finished** IMPs, i.e. medicinal products randomised, packaged, labelled and certified for use in the clinical trial. If there is more than one site or more than one IMP is certified, use extra pages and give each IMP its number from section D.1.1 or D.8.2 In the case of multiple sites indicate the product certified by each site

D.9.1	Do not fill in section D.9.2 for an IMP that: <i>Has a MA in the EU <b>and</b></i> <i>Is sourced from the EU market <b>and</b></i> <i>Is used in the trial without modification( e.g. not overencapsulated) <b>and</b></i> <i>The packaging and labelling is carried out for local use only as per article 9.2. of the Directive 2005/28/EC (GCP Directive)</i> If all these conditions are met tick • and list the number(s) of each IMP including placebo from sections D.1.1 and D.8.2 to which this applies <b>PR1</b> <b>PL1</b>
-------	--

<b>D.9.2</b>	<b>Who is responsible in the Community for the certification of the finished IMPs?</b>	
	This site is responsible for certification of (list the number(s) of each IMP including placebo from sections D.1.1 and D.8.2):	<b>PR1</b>
	please tick the appropriate box:	<b>PL1</b>
D.9.2.1	Manufacturer	<b>Yes •</b>
D.9.2.2	Importer	<b>No •</b>
D.9.2.3	Name of the organisation:	<b>Hospital Pharmacy of the Capital Region og Denmark</b>
D.9.2.4	Address:	
D.9.2.4.1	Street Address	<b>Marielundsvej 25</b>
D.9.2.4.2	Town/City	<b>Herlev</b>
D.9.2.4.3	Post Code	<b>2730</b>
D.9.2.4.4	Country	<b>Denmark</b>
D.9.2.5	Give the manufacturing authorisation number:	
D.9.2.5.1	If No authorisation, give the reasons: <b>This is a hospital pharmacy and they have no authorisation number.</b>	

Where the product does not have a MA in the EU, but is supplied in bulk and final packaging and labelling for local use is carried out in accordance with article 9.2 of Directive 2005/28/EC (GCP Directive) then enter the site where the product was finally certified for release by the Qualified Person for use in the clinical trial at D.9.2 above.

## E. GENERAL INFORMATION ON THE TRIAL

This section should be used to provide information about the aims, scope and design of the trial. When the protocol includes a sub-study in the MS concerned section E.2.3 should be completed providing information about the sub-study. To identify it check the sub-study box in the 'Objective of the trial' question below.

<b>E.1 MEDICAL CONDITION OR DISEASE UNDER INVESTIGATION</b>																																																			
E.1.1	Specify the medical condition(s) to be investigated <sup>23</sup> (free text): <b>English</b> <b>Treatment of delirium in critically ill adult patients in intensive care unit.</b>																																																		
E.1.1.1	Medical condition in easily understood language <b>English</b> <b>Treatment of psychosis related to critical illness in adult patients admitted to intensive care unit</b>																																																		
E.1.1.2	Therapeutic area <b>Diseases [C] - Nervous System Diseases [C10]</b>																																																		
E.1.2	MedDRA version, system organ class, level, term and classification code <sup>24</sup> :																																																		
	<table border="1"> <thead> <tr> <th>Version</th> <th>System Organ Class</th> <th>Classification Code</th> <th>Term</th> <th>Level</th> </tr> </thead> <tbody> <tr> <td>20.0</td> <td>100000004873</td> <td>10000702</td> <td>Acute delirium</td> <td>LLT</td> </tr> <tr> <td>20.0</td> <td>100000004873</td> <td>10013758</td> <td>Drug-induced delirium</td> <td>LLT</td> </tr> <tr> <td>20.0</td> <td>100000004873</td> <td>10042275</td> <td>Subacute delirium</td> <td>LLT</td> </tr> <tr> <td>20.0</td> <td>100000004873</td> <td>10012220</td> <td>Delirium due to a general medical condition</td> <td>LLT</td> </tr> <tr> <td>20.0</td> <td>100000004873</td> <td>10012226</td> <td>Delirium, cause unknown</td> <td>LLT</td> </tr> <tr> <td>20.0</td> <td>100000004863</td> <td>10050233</td> <td>Delirium on emergence</td> <td>LLT</td> </tr> <tr> <td>20.0</td> <td>100000004873</td> <td>10071313</td> <td>Hypoactive delirium</td> <td>LLT</td> </tr> <tr> <td>20.0</td> <td>100000004873</td> <td>10071314</td> <td>Hyperactive delirium</td> <td>LLT</td> </tr> <tr> <td>20.0</td> <td>100000004873</td> <td>10071315</td> <td>Mixed delirium</td> <td>LLT</td> </tr> </tbody> </table>	Version	System Organ Class	Classification Code	Term	Level	20.0	100000004873	10000702	Acute delirium	LLT	20.0	100000004873	10013758	Drug-induced delirium	LLT	20.0	100000004873	10042275	Subacute delirium	LLT	20.0	100000004873	10012220	Delirium due to a general medical condition	LLT	20.0	100000004873	10012226	Delirium, cause unknown	LLT	20.0	100000004863	10050233	Delirium on emergence	LLT	20.0	100000004873	10071313	Hypoactive delirium	LLT	20.0	100000004873	10071314	Hyperactive delirium	LLT	20.0	100000004873	10071315	Mixed delirium	LLT
Version	System Organ Class	Classification Code	Term	Level																																															
20.0	100000004873	10000702	Acute delirium	LLT																																															
20.0	100000004873	10013758	Drug-induced delirium	LLT																																															
20.0	100000004873	10042275	Subacute delirium	LLT																																															
20.0	100000004873	10012220	Delirium due to a general medical condition	LLT																																															
20.0	100000004873	10012226	Delirium, cause unknown	LLT																																															
20.0	100000004863	10050233	Delirium on emergence	LLT																																															
20.0	100000004873	10071313	Hypoactive delirium	LLT																																															
20.0	100000004873	10071314	Hyperactive delirium	LLT																																															
20.0	100000004873	10071315	Mixed delirium	LLT																																															
E.1.3	Is any of the conditions being studied a rare disease <sup>25</sup> ? <b>No •</b>																																																		

<b>E.2 OBJECTIVE OF THE TRIAL</b>	
E.2.1	Main objective: <b>English</b> <b>To assess benefits and harms of haloperidol in adult, critically ill patients with delirium in the ICU. The primary objective is to determine, if haloperidol treatment in ICU patients with delirium will increase the number of days alive out of the hospital within 90 days. This primary objective includes 90 days mortality and length of hospital stay within 90 days after randomisation.</b>
E.2.2	Secondary objectives: <b>English</b> <b>To investigate if haloperidol as compared with placebo in ICU patients with delirium will change the:</b> <ul style="list-style-type: none"> <li>- Number of days alive without delirium or coma in the ICU</li> <li>- Number of patients with one or more adverse reactions and/or the total number of adverse reactions to haloperidol compared with placebo.</li> <li>- Number of patients needing one or more doses of escape medicine and or the dosages of escape medicine per patient in the haloperidol Group compared with the placebo group</li> <li>- Number of days alive without mechanical ventilation in the 90-day trial period</li> <li>- One-year mortality after inclusion</li> <li>- Measurement of cognitive function one year after inclusion on selected trial sites.</li> <li>- A health economic analysis will be performed.</li> </ul>
E.2.3	Is there a sub-study? <b>No •</b>

E.2.3.1 If 'Yes', give the full title, date and version of each sub-study and their related objectives:

**E.3 PRINCIPAL INCLUSION CRITERIA (list the most important)**

**English**

- **Acute admission to the ICU AND**
- **Age  $\geq$  18 years AND**
- **Diagnosed delirium with a validated screening tool as either CAM-ICU or ICDSC.**

**E.4 PRINCIPAL EXCLUSION CRITERIA (list the most important)**

**English**

- **Contraindications to haloperidol**
- **Habitual treatment with any antipsychotic medication**
- **Permanently incompetent (e.g. dementia, mental retardation)**
- **Delirium assessment non-applicable (coma or language barriers)**
- **Withdrawal from active therapy or brain death**
- **Fertile women (women < 50 years) with positive urine human chorionic gonadotropin (hCG) or plasma-hCG**
- **Consent according to national regulations not obtainable**
- **Patients under coercive measures by regulatory authorities**
- **Patients with alcohol-induced delirium (delirium tremens)**

**E.5 END POINT(S):**

E.5.1 Primary End Point (repeat as necessary)<sup>26</sup>

**English** **Days alive out of the hospital within 90 days post-randomisation**

E.5.1.1 Timepoint(s) of evaluation of this end point

**English** **90 days post-randomisation**

E.5.2 Secondary End Point (repeat as necessary)

**English**

- 1. Number of days alive without delirium and coma in the ICU**
- 2. Number of patients with one or more serious adverse reactions to haloperidol and total number of serious adverse reactions to haloperidol**
- 3. Usage of escape medicine and dosage of escape medicine per patient**
- 4. Number of days alive without mechanical ventilation in the 90-day period**
- 5. 1-year mortality post-randomisation**
- 6. EQ-5D-5L and EQ-VAS one year after randomisation. Patients who have died will be assigned the lowest possible EQ-5D-5L and EQ-VAS score.**
- 7. Cognitive function 1-year after randomisation as assessed using RBANS score at selected sites.**
- 8. A health economic analysis will be performed. The analytic details will be based on the result of the trial and specified (cost-effectiveness vs. cost-minimisation analyses). Outcomes will be one-year mortality and Quality adjusted Life Years (QALYs). The latter will be conducted on the basis of Eq-5D-5L. The inclusion of QALYs generates a cost-utility analysis.**

E.5.2.1 Timepoint(s) of evaluation of this end point

**English** **Endpoint number 1-4: 90 days post-randomisation**  
**Endpoint number 5-8: 1 year post-randomisation**

<b>E.6 SCOPE OF THE TRIAL – Tick all boxes where applicable</b>		
E.6.1	Diagnosis	<b>No •</b>
E.6.2	Prophylaxis	<b>No •</b>
E.6.3	Therapy	<b>Yes •</b>
E.6.4	Safety	<b>Yes •</b>
E.6.5	Efficacy	<b>Yes •</b>
E.6.6	Pharmacokinetic	<b>No •</b>
E.6.7	Pharmacodynamic	<b>No •</b>
E.6.8	Bioequivalence	<b>No •</b>
E.6.9	Dose Response	<b>No •</b>
E.6.10	Pharmacogenetic	<b>No •</b>
E.6.11	Pharmacogenomic	<b>No •</b>
E.6.12	Pharmacoeconomic	<b>No •</b>
E.6.13	Others	<b>No •</b>
E.6.13.1	If others, specify:	

<b>E.7 TRIAL TYPE AND PHASE<sup>27</sup></b>		
E.7.1	Human pharmacology (Phase I)	<b>No •</b>
Is it:		
E.7.1.1	First administration to humans	<b>No •</b>
E.7.1.2	Bioequivalence study	<b>No •</b>
E.7.1.3	Other:	<b>No •</b>
E.7.1.3.1	If other, please specify:	
E.7.2	Therapeutic exploratory (Phase II)	<b>No •</b>
E.7.3	Therapeutic confirmatory (Phase III)	<b>No •</b>
E.7.4	Therapeutic use(Phase IV)	<b>Yes •</b>

<b>E.8 DESIGN OF THE TRIAL</b>		
E.8.1	Controlled	<b>Yes •</b>
If 'Yes', specify:		
E.8.1.1	Randomised:	<b>Yes •</b>
E.8.1.2	Open:	<b>No •</b>
E.8.1.3	Single blind:	<b>No •</b>
E.8.1.4	Double blind:	<b>Yes •</b>
E.8.1.5	Parallel group:	<b>Yes •</b>
E.8.1.6	Cross over:	<b>No •</b>
E.8.1.7	Other:	<b>No •</b>
E.8.1.7.1	If other specify:	
E.8.2	If controlled, specify the comparator:	
E.8.2.1	Other medicinal product(s)	<b>No •</b>
E.8.2.2	Placebo	<b>Yes •</b>
E.8.2.3	Other	<b>No •</b>
E.8.2.3.1	If 'Yes' to other, specify :	
E.8.2.4	Number of treatment arms in the trial	<b>2</b>
E.8.3	Single site in the Member State concerned (see also section G):	<b>No •</b>
E.8.4	Multiple sites in the Member State concerned(see also section G):	<b>Yes •</b>
E.8.4.1	Number of sites anticipated in Member State concerned	<b>20</b>
E.8.5	Multiple Member States:	<b>Yes •</b>
E.8.5.1	Number of sites anticipated in the EEA:	<b>30</b>
E.8.6	Trial involving sites outside the EEA:	
E.8.6.1	Trial being conducted both within and outside the EEA:	<b>Yes •</b>
E.8.6.2	Trial being conducted completely outside of the EEA:	<b>No •</b>
E.8.6.3	If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:	
<b>Denmark</b>		
<b>Finland</b>		
<b>France</b>		
<b>Italy</b>		
<b>Norway</b>		
<b>Spain</b>		

	<b>Sweden</b>	
	<b>United Kingdom</b>	
E.8.6.4	If E.8.6.1 or E.8.6.2 are Yes, specify the number of sites anticipated outside of the EEA:	<b>1</b>
E.8.7	Trial having an independent data monitoring committee:	<b>Yes •</b>
E.8.8	Definition of the end of trial: If it is the last visit of the last subject, please enter "LVLS". If it is not LVLS provide the definition: <b>English</b>	<b>1 year post-randomisation of the last included patient in the trial</b>
E.8.9	Initial estimate of the duration of the trial <sup>28</sup> (years, months and days)	
E.8.9.1	In the Member State concerned	<b>3 years months days</b>
E.8.9.2	In all countries concerned by the trial	<b>3 years months days</b>
E.8.10	Proposed date of start of recruitment	
E.8.10.1	In the Member State concerned	<b>2018-02-01</b>
E.8.10.2	In any country	<b>2018-02-01</b>

## F. POPULATION OF TRIAL SUBJECTS

<b>F.1 AGE RANGE</b>		
F.1.1	Are the trial subjects under 18? If 'Yes', specify the estimated number of subjects planned in each age range for the whole trial:	<b>No •</b>
	Approx. No. of patients <sup>29</sup>	
F.1.1.1	In utero	( ) <b>No •</b>
F.1.1.2	Preterm newborn infants (up to gestational age < 37 weeks)	( ) <b>No •</b>
F.1.1.3	Newborns (0-27 days)	( ) <b>No •</b>
F.1.1.4	Infants and toddlers (28 days - 23 months)	( ) <b>No •</b>
F.1.1.5	Children (2-11 years)	( ) <b>No •</b>
F.1.1.6	Adolescents (12-17 years)	( ) <b>No •</b>
F.1.2	Adults (18-64 years)	(200) <b>Yes •</b>
F.1.3	Elderly (>= 65 years)	(800) <b>Yes •</b>
<b>F.2 GENDER</b>		
F.2.1	Female	<b>Yes •</b>
F.2.2	Male	<b>Yes •</b>
<b>F.3 GROUP OF TRIAL SUBJECTS</b>		
F.3.1	Healthy volunteers	<b>No •</b>
F.3.2	Patients	<b>Yes •</b>
F.3.3	Specific vulnerable populations	<b>Yes •</b>
F.3.3.1	Women of child bearing potential not using contraception	<b>Yes •</b>
F.3.3.2	Women of child bearing potential using contraception	<b>Yes •</b>
F.3.3.3	Pregnant women	<b>No •</b>
F.3.3.4	Nursing women	<b>Yes •</b>
F.3.3.5	Emergency situation	<b>Yes •</b>
F.3.3.6	Subjects incapable of giving consent personally	<b>Yes •</b>
F.3.3.6.1	If 'Yes', specify: <b>English</b> <b>Patients (ICU patients) with delirium are temporarily incompetent (it is the hallmark of delirium), to investigate the treatment of this condition we need to enroll patients without consent. Consent will be obtained according to national law.</b>	
F.3.3.7	Others:	<b>No •</b>
F.3.3.7.1	If 'Yes', specify:	
<b>F.4 PLANNED NUMBER OF SUBJECTS TO BE INCLUDED:</b>		
F.4.1	In the member state	<b>750</b>
F.4.2	For a multinational trial:	
F.4.2.1	In the EEA	<b>850</b>
F.4.2.2	In the whole clinical trial	<b>1000</b>
<b>F.5 PLANS FOR TREATMENT OR CARE AFTER THE SUBJECT HAS ENDED HIS/HER PARTICIPATION IN THE TRIAL. please specify (free text):</b>		
	<b>English</b> <b>None</b>	

**G. CLINICAL TRIAL SITES/INVESTIGATORS IN THE MEMBER STATE  
CONCERNED BY THIS REQUEST**

<b>G.1</b>	<b>CO-ORDINATING INVESTIGATOR (for multicentre trial) and principal investigator (for single centre trial)</b>	
G.1.1	Given name:	<b>Nina Christine</b>
G.1.2	Middle name, if applicable:	
G.1.3	Family name:	<b>Andersen-Ranberg</b>
G.1.4	Qualification (MD.....)	<b>MD</b>
G.1.5	Professional address:	
G.1.5	Institution name	<b>Zealand University Hospital, Koege</b>
G.1.5	Institution department	<b>Department of Anaesthesiology</b>
G.1.5.1	Street address	<b>Lykkebaekvej 1</b>
G.1.5.2	Town/city	<b>Koege</b>
G.1.5.3	Post code	<b>4600</b>
G.1.5.4	Country	<b>Denmark</b>
G.1.6	Telephone number:	<b>+45 47326493</b>
G.1.7	Fax number:	
G.1.8	E-mail:	<b>ncan@regionsjaelland.dk</b>

<b>G.2</b>	<b>PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>	
G.2.1	Given name:	<b>Sven-Olaf</b>
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	<b>Weber</b>
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Aalborg University Hospital</b>
G.2.5	Institution department	<b>Department of Anaesthesiology</b>
G.2.5.1	Street address	<b>Hobrovej 18-22</b>
G.2.5.2	Town/city	<b>Aalborg</b>
G.2.5.3	Post code	<b>9000</b>
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	

<b>G.2</b>	<b>PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>	
G.2.1	Given name:	<b>Carsten</b>
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	<b>Thee</b>
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Aabenraa Sygehus</b>
G.2.5	Institution department	<b>Department of Anaesthesiology</b>
G.2.5.1	Street address	<b>Kresten Philipsens Vej 15</b>
G.2.5.2	Town/city	<b>Aabenraa</b>
G.2.5.3	Post code	<b>6200</b>
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	

<b>G.2 PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>		
G.2.1	Given name:	<b>Anne</b>
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	<b>Lindhart</b>
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Bispebjerg Hospital</b>
G.2.5	Institution department	<b>Department og anaesthesiology</b>
G.2.5.1	Street address	<b>Bispebjerg Bakke 23</b>
G.2.5.2	Town/city	<b>Copenhagen NV</b>
G.2.5.3	Post code	<b>2400</b>
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	

<b>G.2 PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>		
G.2.1	Given name:	<b>Troels</b>
G.2.2	Middle name, if applicable:	<b>Bek</b>
G.2.3	Family name:	<b>Jensen</b>
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Herning Sygehus</b>
G.2.5	Institution department	<b>Department of Anaesthesiology</b>
G.2.5.1	Street address	<b>Gl. Landevej 61</b>
G.2.5.2	Town/city	<b>Herning</b>
G.2.5.3	Post code	<b>7400</b>
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	

<b>G.2 PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>		
G.2.1	Given name:	<b>Hans Henrik</b>
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	<b>Bülow</b>
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Holbæk Sygehus</b>
G.2.5	Institution department	<b>Department of Anaesthesiology</b>
G.2.5.1	Street address	<b>Smedelundsgade 60</b>
G.2.5.2	Town/city	<b>Holbæk</b>
G.2.5.3	Post code	<b>4300</b>
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	<b>hhbu@regionsjaelland.dk</b>

<b>G.2 PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>		
G.2.1	Given name:	<b>Nilanjan</b>
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	<b>Dey</b>



G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Holstebro Sygehus</b>
G.2.5	Institution department	
G.2.5.1	Street address	
G.2.5.2	Town/city	
G.2.5.3	Post code	
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	

<b>G.2</b>	<b>PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>	
G.2.1	Given name:	<b>Morten</b>
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	<b>Borup</b>
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Kolding Sygehus</b>
G.2.5	Institution department	
G.2.5.1	Street address	<b>Sygehusvej 24</b>
G.2.5.2	Town/city	<b>Kolding</b>
G.2.5.3	Post code	<b>6000</b>
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	<b>morten.borup@rsyd.dk</b>

<b>G.2</b>	<b>PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>	
G.2.1	Given name:	<b>Morten</b>
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	<b>Bestle</b>
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Nordsjællands hospital</b>
G.2.5	Institution department	
G.2.5.1	Street address	
G.2.5.2	Town/city	
G.2.5.3	Post code	
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	

<b>G.2</b>	<b>PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>	
G.2.1	Given name:	<b>Anders</b>
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	<b>Perner</b>
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Rigshospitalet, klinik for intensiv terapi 4131</b>
G.2.5	Institution department	
G.2.5.1	Street address	
G.2.5.2	Town/city	

G.2.5.3	Post code	
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	

<b>G.2</b>	<b>PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>	
G.2.1	Given name:	<b>Susanne</b>
G.2.2	Middle name, if applicable:	<b>Andi</b>
G.2.3	Family name:	<b>Iversen</b>
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Slagelse Sygehus</b>
G.2.5	Institution department	
G.2.5.1	Street address	
G.2.5.2	Town/city	
G.2.5.3	Post code	
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	

<b>G.2</b>	<b>PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>	
G.2.1	Given name:	<b>Carsten</b>
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	<b>Thee</b>
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Sønderborg Sygehus</b>
G.2.5	Institution department	
G.2.5.1	Street address	<b>Sydvang 1</b>
G.2.5.2	Town/city	<b>Sønderborg</b>
G.2.5.3	Post code	<b>6400</b>
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	<b>carsten.thee@rsyd.dk</b>

<b>G.2</b>	<b>PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>	
G.2.1	Given name:	<b>Thomas</b>
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	<b>Mohr</b>
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Gentofte Hospital</b>
G.2.5	Institution department	
G.2.5.1	Street address	<b>Kildegaardsvej 28</b>
G.2.5.2	Town/city	<b>Gentofte</b>
G.2.5.3	Post code	<b>2900</b>
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	<b>thomas.mohr@regionh.dk</b>

<b>G.2 PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>		
G.2.1	Given name:	<b>Sofie</b>
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	<b>Andreasen</b>
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Herlev Hospital</b>
G.2.5	Institution department	
G.2.5.1	Street address	<b>Herlev Ringvej 75</b>
G.2.5.2	Town/city	<b>Herlev</b>
G.2.5.3	Post code	<b>2730</b>
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	<b>anne.sofie.andreasen@regionh.dk</b>

<b>G.2 PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>		
G.2.1	Given name:	<b>Thomas</b>
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	<b>Hildebrandt</b>
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Zealand University Hospital, Roskilde</b>
G.2.5	Institution department	
G.2.5.1	Street address	<b>Sygehusvej 10</b>
G.2.5.2	Town/city	<b>Roskilde</b>
G.2.5.3	Post code	<b>4000</b>
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	<b>thi@regionsjaelland.dk</b>

<b>G.2 PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>		
G.2.1	Given name:	<b>Helle</b>
G.2.2	Middle name, if applicable:	
G.2.3	Family name:	<b>Scharling Pedersen</b>
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Nykøbing Falster Hospital</b>
G.2.5	Institution department	
G.2.5.1	Street address	<b>Fjordvej 15</b>
G.2.5.2	Town/city	<b>Nykøbing Falster</b>
G.2.5.3	Post code	<b>4800</b>
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	<b>hbpn@regionsjaelland.dk</b>

<b>G.2 PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)</b>		
G.2.1	Given name:	<b>Louise</b>
G.2.2	Middle name, if applicable:	

G.2.3	Family name:	<b>Gramstrup Nielsen</b>
G.2.4	Qualification (MD.....)	
G.2.5	Professional address:	
G.2.5	Institution name	<b>Odense University Hospital</b>
G.2.5	Institution department	
G.2.5.1	Street address	<b>J.B. Winsløvsvej 4</b>
G.2.5.2	Town/city	<b>5000 Odense C</b>
G.2.5.3	Post code	
G.2.5.4	Country	<b>Denmark</b>
G.2.6	Telephone number:	
G.2.7	Fax number:	
G.2.8	E-mail:	<b>louise.gramstrup.nielsen@rsyd.dk</b>

<b>G.3</b>	<b>CENTRAL TECHNICAL FACILITIES TO BE USED IN THE CONDUCT OF THE TRIAL</b>	
	<b>Laboratory or other technical facility, in which the measurement or assessment of the main evaluation criteria are centralised</b> (repeat as needed for multiple organisations).	
G.3.1	Name of organisation:	
G.3.2	Department	
G.3.3	Name of contact person:	
G.3.3.1	Given name	
G.3.3.2	Middle name	
G.3.3.3	Family name	
G.3.4	Address:	
G.3.4.1	Street address	
G.3.4.2	Town/city	
G.3.4.3	Post code	
G.3.4.4	Country	
G.3.5	Telephone number:	
G.3.6	Fax number:	
G.3.7	E-mail:	
G.3.8	Enter the details of any duties subcontracted to this central technical facility in this trial	
G.3.8.1	Routine clinical pathology testing	<b>Yes ? No ? Not Answered ?</b>
G.3.8.2	Clinical chemistry	<b>Yes ? No ? Not Answered ?</b>
G.3.8.3	Clinical haematology	<b>Yes ? No ? Not Answered ?</b>
G.3.8.4	Clinical microbiology	<b>Yes ? No ? Not Answered ?</b>
G.3.8.5	Histopathology	<b>Yes ? No ? Not Answered ?</b>
G.3.8.6	Serology/ endocrinology	<b>Yes ? No ? Not Answered ?</b>
G.3.8.7	Analytical chemistry	<b>Yes ? No ? Not Answered ?</b>
G.3.8.8	ECG analysis/ review	<b>Yes ? No ? Not Answered ?</b>
G.3.8.9	Medical image analysis/ review - X-ray, MRI, ultrasound, etc.	<b>Yes ? No ? Not Answered ?</b>
G.3.8.10	Primary/ surrogate endpoint test	<b>Yes ? No ? Not Answered ?</b>
G.3.8.11	Other Duties subcontracted?	<b>Yes ? No ? Not Answered ?</b>
G.3.8.11.1	If 'Yes', specify the other duties	

<b>G.4</b>	<b>NETWORKS TO BE INVOLVED IN THE TRIAL (e.g. Paediatric Networks involved in the trial)</b>	
G.4.1	Name of organisation:	<b>Scandinavian Critical Care Trials Group</b>
G.4.2	Name of contact person:	
G.4.2.1	Given name	<b>Anders</b>
G.4.2.2	Middle name	
G.4.2.3	Family name	<b>Perner</b>
G.4.3	Address:	
G.4.3.1	Street address	<b>Blegdamsvej 9</b>
G.4.3.2	Town/city	<b>Copenhagen</b>
G.4.3.3	Post code	<b>2100</b>
G.4.3.4	Country	<b>Denmark</b>

G.4.4	Telephone number:	
G.4.5	Fax number:	
G.4.6	E-mail:	<b>anders.perner@regionh.dk</b>
G.4.7	Activities carried out by the network:	

<b>G.4</b>	<b>NETWORKS TO BE INVOLVED IN THE TRIAL (e.g. Paediatric Networks involved in the trial)</b>	
G.4.1	Name of organisation:	<b>Copenhagen Trial Unit</b>
G.4.2	Name of contact person:	
G.4.2.1	Given name	<b>Jørn</b>
G.4.2.2	Middle name	
G.4.2.3	Family name	<b>Wetterslev</b>
G.4.3	Address:	
G.4.3.1	Street address	<b>Blegdamsvej 9</b>
G.4.3.2	Town/city	<b>Copenhagen</b>
G.4.3.3	Post code	<b>2100</b>
G.4.3.4	Country	<b>Denmark</b>
G.4.4	Telephone number:	
G.4.5	Fax number:	
G.4.6	E-mail:	<b>wetterslev@ctu.dk</b>
G.4.7	Activities carried out by the network:	

<b>G.4</b>	<b>NETWORKS TO BE INVOLVED IN THE TRIAL (e.g. Paediatric Networks involved in the trial)</b>	
G.4.1	Name of organisation:	<b>Centre for Research in Intensive Care (CRIC)</b>
G.4.2	Name of contact person:	
G.4.2.1	Given name	<b>Anders</b>
G.4.2.2	Middle name	
G.4.2.3	Family name	<b>Perner</b>
G.4.3	Address:	
G.4.3.1	Street address	<b>Blegdamsvej 9</b>
G.4.3.2	Town/city	<b>Copenhagen</b>
G.4.3.3	Post code	<b>2100</b>
G.4.3.4	Country	<b>Denmark</b>
G.4.4	Telephone number:	
G.4.5	Fax number:	
G.4.6	E-mail:	<b>Anders.perner@regionh.dk</b>
G.4.7	Activities carried out by the network:	

<b>G.5</b>	<b>ORGANISATIONS TO WHOM THE SPONSOR HAS TRANSFERRED TRIAL RELATED DUTIES AND FUNCTIONS</b>	
G.5.1	<b>Has the sponsor transferred any major or all the sponsor's trial related duties and functions to another organisation or third party?</b>	<b>Yes •</b>
Repeat as necessary for multiple organisations:		
G.5.1.1	Organisation name:	<b>GCP Unit</b>
G.5.1.2	Organisation department	<b>Copenhagen University Hospital</b>
G.5.1.3	Name of contact person :	
G.5.1.3.1	Given name	<b>Pernille</b>
G.5.1.3.2	Middle name	
G.5.1.3.3	Family name	<b>Ask Aabo</b>
G.5.1.4	Address:	
G.5.1.4.1	Street address	<b>Bispebjerg Hospital, building 51, 3rd, Bispebjerg Bakke 23</b>
G.5.1.4.2	Town/city	<b>Copenhagen</b>

G.5.1.4.3	Post code	<b>2400</b>	
G.5.1.4.4	Country	<b>Denmark</b>	
G.5.1.5	Telephone number:	<b>+45 38635794</b>	
G.5.1.6	Fax number:		
G.5.1.7	E-mail:	<b>pernille.ask.aabo@regionh.dk</b>	
G.5.1.8	All tasks of the sponsor		<b>Not Answered •</b>
G.5.1.9	Monitoring		<b>Yes •</b>
G.5.1.10	Regulatory (e.g. preparation of applications to CA and ethics committee)		<b>Not Answered •</b>
G.5.1.11	Investigator recruitment		<b>Not Answered •</b>
G.5.1.12	IVRS <sup>30</sup> – treatment randomisation		<b>Not Answered •</b>
G.5.1.13	Data management		<b>Not Answered •</b>
G.5.1.14	E-data capture		<b>Not Answered •</b>
G.5.1.15	SUSAR reporting		<b>Not Answered •</b>
G.5.1.16	Quality assurance auditing		<b>Not Answered •</b>
G.5.1.17	Statistical analysis		<b>Not Answered •</b>
G.5.1.18	Medical writing		<b>Not Answered •</b>
G.5.1.19	Other duties subcontracted?		<b>Not Answered •</b>
G.5.1.19.1	If 'Yes' to other, please specify:		<b>Not Answered •</b>

**H. COMPETENT AUTHORITY / ETHICS COMMITTEE IN THE MEMBER STATE CONCERNED BY THIS REQUEST**

<b>H.1 TYPE OF APPLICATION</b>		
If this application is addressed to the Competent Authority, please tick the Ethics Committee box and give information on the Ethics committee concerned. If this application is addressed to the Ethics Committee, please tick the Competent Authority box and give the information on the Competent Authority concerned.		
H.1.1	Competent Authority	<b>No ●</b>
H.1.2	Ethics Committee	<b>Yes ●</b>
<b>H.2 INFORMATION ON ETHICS COMMITTEE</b>		
H.2.1	Name:	<b>The Comitée on Health Research Ethics for the Zealand Region</b>
H.2.2	Address	
H.2.2.1	Street address	<b>Alléen 15</b>
H.2.2.2	Town/city	<b>Soroe</b>
H.2.2.3	Post code	<b>4180</b>
H.2.2.4	Country	<b>Denmark</b>
H.2.3	Date of submission:	<b>2017-09-18</b>
<b>H.3 OPINION</b>		
H.3.1	To be requested	<b>No ●</b>
H.3.2	Pending	<b>Yes ●</b>
H.3.3	Given	<b>No ●</b>
	If 'Given', specify:	
H.3.3.1	Date of opinion:	
H.3.3.2	Opinion favourable	<b>No ●</b>
H.3.3.3	Opinion not favourable	<b>No ●</b>
	If not favourable, give:	
H.3.3.3.1	The reasons	
H.3.3.3.2	The eventual anticipated date of resubmission:	

## I. SIGNATURE OF THE APPLICANT IN THE MEMBER STATE

<b>I.1</b>	I hereby confirm that /confirm on behalf of the sponsor (delete which is not applicable) that: <ul style="list-style-type: none"><li>• the information provided is complete;</li><li>• the attached documents contain an accurate account of the information available;</li><li>• the clinical trial will be conducted in accordance with the protocol; and</li><li>• the clinical trial will be conducted, and SUSARs and result-related information will be reported, in accordance with the applicable legislation.</li></ul>
------------	--

<b>I.2</b>	<b>APPLICANT OF THE REQUEST FOR THE COMPETENT AUTHORITY</b> (as stated in section C.1):
I.2.1	Date:
I.2.2	Signature <sup>31</sup> :
I.2.3	Print name:

<b>I.3</b>	<b>APPLICANT OF THE REQUEST FOR THE ETHICS COMMITTEE</b> (as stated in section C.2):
I.3.1	Date:
I.3.2	Signature <sup>32</sup> :
I.3.3	Print name:



## ENDNOTES

- <sup>1</sup> Any translation of the protocol should be assigned the same date and version as those in the original document.
- <sup>2</sup> International Standard Randomised Controlled Trial Number. Sponsors may wish to use an International Standardised Random Controlled Trial Number (ISRCTN) to identify their trial in addition to the EudraCT number; for instance if their trial is part of a multinational trial with sites outside the Community. They can obtain the number and guidance from the Current Controlled Trials website <http://www.controlled-trials.com/isrctn> to which there is a link from the EudraCT database website <http://eudract.ema.europa.eu>. When available they should provide it in Section A.6 of the application form.
- <sup>3</sup> US National Clinical Trial (NCT) Numbers required on the FDA clinical trial application form.
- <sup>4</sup> For a resubmission following previous withdrawal of an application or unfavourable opinion of an ethics committee, or previous withdrawal of an application or refusal of a request by the competent authority, enter a letter in the sequence, A for first resubmission, B for second, C for third et seq.
- <sup>5</sup> In accordance with Article 19 of Directive 2001/20/EC.
- <sup>6</sup> The contact point should give functional information rather than details of one "person", in order to avoid the need for update and maintenance of these contact details.
- <sup>7</sup> This requires a EudraLink account. (See <https://eudract.ema.europa.eu/document.html> for details)
- <sup>8</sup> According to national legislation.
- <sup>9</sup> Available from the Summary of Product Characteristics (SmPC)
- <sup>10</sup> According to the Community register on orphan medicinal products (Regulation (EC) n° 141/2000): <http://ec.europa.eu/enterprise/pharmaceuticals/register/index.htm>
- <sup>11</sup> Committee for Medicinal Products for Human Use of the European Medicines Agency
- <sup>12</sup> To be provided only when there is No trade name. This is the name routinely used by a sponsor to identify the IMP in the CT documentation (protocol, IB...).
- <sup>13</sup> To be provided only when there is No trade name. This is a code designated by the sponsor which represents the name routinely used by the sponsor to identify the product in the CT documentation. For example, a code may be used for combinations of drugs or drugs and devices.
- <sup>14</sup> Available from the Summary of Product Characteristics (SmPC).
- <sup>15</sup> Chemical Abstracts Service.
- <sup>16</sup> Complete also section D.4 Cell therapy as defined in Annex 1 part IV of Directive 2001/83/EC as amended.
- <sup>17</sup> Complete also section D.5 Gene Therapy as defined in Annex 1 part IV of Directive 2001/83/EC as amended.
- <sup>18</sup> Complete also section D.6 - Tissue Engineered Product as defined in Article 2(1)(b) of Regulation 1394/2007/EC.
- <sup>19</sup> Complete also section D.7
- <sup>20</sup> The mode of action should briefly describe the chemical, biochemical, immunological or biological means the IMP uses to effect its pharmaceutical action.
- <sup>21</sup> Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/2007 19 July 2007
- <sup>22</sup> In accordance with paragraph 38 of Annex 13 of Volume 4 of the Rules Governing Medical Products in the European Union.
- <sup>23</sup> In the case of healthy volunteer trials, the intended indication for the product under development should be provided.
- <sup>24</sup> Applicants are encouraged to provide the MedDRA lower level term if applicable and classification code. These can be accessed from the EMEA EudraCT website (<http://eudract.ema.europa.eu/>).
- <sup>25</sup> Points to consider on the calculation and reporting of the prevalence of a condition for Orphan drug designation: COM/436/01 (<http://www.ema.europa.eu/htms/human/orphans/intro.htm>).
- <sup>26</sup> The protocol will usually identify a single primary end point but there may be a co-primary end point in some cases and/or a number of secondary end points.
- <sup>27</sup> The descriptions of the trial types provided are those recommended in preference to Phases. See page 5 of Community guideline CPMP/ICH/291/95. The development of a new indication after initial approval of a medicine should be considered as a new development plan.
- <sup>28</sup> From the first inclusion until the last visit of the last subject.
- <sup>29</sup> These numbers will be initial estimates. Applicants will not be required to update this information nor do they constitute an authorisation or restriction on the inclusion of these numbers of patients in the trial. The numbers of subjects whose inclusion is authorised are those set out in the authorised version of the protocol, or subsequent authorised amendments.
- <sup>30</sup> Interactive Voice Response System: commonly used for randomisation of treatment and controlling the shipment of stock of product.
- <sup>31</sup> On an application to the Competent Authority only, the applicant to the Competent Authority needs to sign.

<sup>32</sup> On an application to the Ethics Committee only, the applicant to the Ethics Committee needs to sign.